Ratings by Maxim Group (Michael Okunewitch)
| Date | Company | Symbol | Type | Rating (Past) |
PT (Past) |
Start $ (End $) |
% Chg. | Details |
|---|---|---|---|---|---|---|---|---|
| 7/16/2026 | AtaiBeckley Inc | ATAI | Downgrade | Hold (Buy) |
5.36 (7.22) |
34.7% | Details | |
| 6/18/2026 | VolitionRX | VNRX | New Coverage | Buy (N/A) |
1.37 (1.10) |
-19.71% | Details | |
| 5/28/2026 | HCW Biologics Inc. | HCWB | Maintain | Buy (N/A) |
|
Details | ||
| 5/20/2026 | Gilead Sciences | GILD | Upgrade | Buy (Hold) |
130.50 (134.28) |
2.9% | Details | |
| 5/11/2026 | Longeveron | LGVN | Downgrade | Hold (Buy) |
0.85 (0.62) |
-27.06% | Details | |
| 5/11/2026 | 20/20 Biolabs | AIDX | New Coverage | Buy (N/A) |
1.37 (0.52) |
-62.04% | Details | |
| 5/4/2026 | FibroBiologics | FBLG | Downgrade | Hold (Buy) |
1.46 (0.83) |
-43.15% | Details | |
| 4/8/2026 | NervGen Pharma Corp | NGEN | Maintain | Buy (N/A) |
|
Details | ||
| 3/6/2026 | Mainz Biomed B.V. | MYNZ | Downgrade | Hold (Buy) |
0.81 (0.84) |
3.7% | Details | |
| 2/19/2026 | Evaxion Biotech | EVAX | New Coverage | Buy (N/A) |
3.32 (3.08) |
-7.23% | Details | |
| 9/23/2025 | Citius Oncology Inc. | CTOR | Upgrade | Buy (Hold) |
1.78 (0.69) |
-61.24% | Details | |
| 7/23/2025 | Anebulo Pharmaceuticals | ANEB | Downgrade | Hold (Buy) |
1.83 (0.36) |
-80.33% | Details | |
| 5/29/2025 | HCW Biologics Inc. | HCWB | Maintain | Buy (N/A) |
|
Details | ||
| 5/23/2025 | Citius Oncology Inc. | CTOR | Downgrade | Hold (Buy) |
0.91 (0.69) |
-24.18% | Details | |
| 5/15/2025 | Anebulo Pharmaceuticals | ANEB | Maintain | Buy (N/A) |
|
Details | ||
| 5/1/2025 | Radiopharm Theranostics | RADX | New Coverage | Buy (N/A) |
3.91 (4.43) |
13.3% | Details | |
| 2/20/2025 | Chemomab Therapeutics | CMMB | Maintain | Buy (N/A) |
|
Details | ||
| 2/14/2025 | Mainz Biomed B.V. | MYNZ | New Coverage | Buy (N/A) |
6.53 (0.81) |
-87.6% | Details | |
| 11/27/2024 | Citius Oncology Inc. | CTOR | New Coverage | Buy (N/A) |
1.00 (0.69) |
-31% | Details | |
| 11/8/2024 | Gilead Sciences | GILD | Maintain | (N/A) |
|
Details | ||
| 10/15/2024 | Ocugen, Inc. | OCGN | New Coverage | Buy (N/A) |
0.95 (1.36) |
43.16% | Details | |
| 9/24/2024 | FibroBiologics | FBLG | New Coverage | Buy (N/A) |
2.76 (1.46) |
-47.1% | Details | |
| 6/14/2024 | Rani Therapeutics Holdsing s | RANI | New Coverage | Buy (N/A) |
4.08 (0.70) |
-82.84% | Details | |
| 5/13/2024 | Chemomab Therapeutics | CMMB | New Coverage | Buy (N/A) |
0.84 (1.56) |
85.71% | Details | |
| 12/7/2023 | Adamis Pharma | DMK | New Coverage | Buy (N/A) |
0.61 (0.23) |
-62.3% | Details | |
| 9/21/2023 | Anebulo Pharmaceuticals | ANEB | New Coverage | Buy (N/A) |
3.48 (0.36) |
-89.66% | Details | |
| 9/12/2023 | Irwin Naturals | IWINF | Maintain | Buy (N/A) |
|
Details | ||
| 8/9/2023 | Kiora Pharmaceuticals | KPRX | Maintain | Buy (N/A) |
|
Details | ||
| 7/21/2023 | Lexaria Bioscience | LEXX | New Coverage | Buy (N/A) |
0.76 (0.64) |
-15.79% | Details | |
| 6/28/2023 | BioRestorative Therapies Inc. | BRTX | Maintain | Buy (N/A) |
|
Details | ||
| 2/9/2023 | Kiora Pharmaceuticals | KPRX | Upgrade | Buy (Hold) |
6.94 (2.63) |
-62.1% | Details | |
| 12/22/2022 | MediWound Ltd | MDWD | New Coverage | Buy (N/A) |
11.00 (14.61) |
32.82% | Details | |
| 9/28/2022 | BioRestorative Therapies Inc. | BRTX | New Coverage | Buy (N/A) |
2.46 (0.33) |
-86.59% | Details | |
| 8/15/2022 | Kiora Pharmaceuticals | KPRX | Downgrade | Hold (Buy) |
0.16 (2.63) |
1543.75% | Details | |
| 3/24/2022 | Longeveron | LGVN | New Coverage | Buy (N/A) |
6.52 (0.85) |
-86.96% | Details | |
| 1/19/2022 | Kiora Pharmaceuticals | KPRX | New Coverage | Buy (N/A) |
0.80 (2.63) |
228.75% | Details |
